Worldwide Pharmaceutical Fine Chemicals Industry to 2030 – Growing Awareness in the African Region Presents Opportunities

DUBLIN, Aug. 27, 2020 /PRNewswire/ — The “Pharmaceutical Fine Chemicals Market Research Report: By Drug Type, Product, Application – Global Industry Analysis and Growth Forecast to 2030” report has...

DUBLIN, Aug. 27, 2020 /PRNewswire/ — The “Pharmaceutical Fine Chemicals Market Research Report: By Drug Type, Product, Application – Global Industry Analysis and Growth Forecast to 2030” report has been added to ResearchAndMarkets.com’s offering.

The global pharmaceutical fine chemicals market generated a revenue of $100.3 billion in 2019, and it is predicted to grow at a 6.2% CAGR during the forecast period (2020-2030).

The major driving factors of the market are the surging geriatric population, and rapid expansion of the pharmaceutical industry in the Asia-Pacific (APAC) region. In terms of drug type, the pharmaceutical fine chemicals market is bifurcated into non-proprietary and proprietary, between which, the proprietary drug bifurcation accounted for the larger revenue share of the market.

This is because of the fact that the production of these drugs requires high capital investment, compliance to stringent regulations, strong research & development efforts, and adequate quality control measures. On the basis of product, the pharmaceutical fine chemicals market is categorized into active ingredients, basic building blocks, and advanced intermediaries. Out of these, the active ingredients category is predicted to advance at the fastest pace during the forecast period. These are the most important component of the drug, since they accomplish the purpose of medication, owing to which, their demand is predicted to increase.

The surging aging population is one of the major driving factors of the pharmaceuticals fine chemicals market. According to the latest World Population Ageing report by the United Nations Department of Economic and Social Affairs, the number of people aged 65 and above is expected to increase to 1.5 billion by 2050. Because of their physical weakness and immunocompromised nature, aged people fall sick more often than adults and children, which is why, the need for medical drugs is higher for them. This is further creating the need for chemicals to produce drugs.

The growing awareness in Africa is expected to open up wide opportunities for players operating in the pharmaceuticals fine chemical market. The governments of various countries in the region, such as Nigeria and Kenya, are encouraging the local production of medical drugs, which is primarily aimed at improving the accessibility of these products. Countries in the region are further focusing on enhancing the public health and aiming to have a larger and healthier workforce for the benefit of national economy. These aspects are projected to result in the growth of the market.

When application is taken into consideration, the pharmaceutical fine chemicals market is divided into musculoskeletal, cardiovascular, gastrointestinal, neurological, respiratory, and oncological. The largest revenue share of the market during the forecast period is predicted to be held by the cardiovascular division. This is due to the growing prevalence of cardiovascular diseases, such as hypertension, stroke, coronary artery disease, and arrhythmias. This is leading to the increasing demand for heart medication, which, in turn, is driving the demand for pharmaceutical fine chemicals.

Geographically, North America accounted for the major revenue share of the pharmaceutical fine chemicals market during the historical period (2014-2019). This is because of the fact that the region has the largest pharmaceutical industry in the region and further accounts for increased high healthcare expenditure. In addition to this, various drug manufacturers in the region are pursuing research & development activities for coming up with medication for the rising number of presently-untreatable diseases.

Key Topics Covered:

Chapter 1. Research Background

Chapter 2. Research Methodology


Chapter 3. Executive Summary

Chapter 4. Introduction

4.1 Definition of Market Segments

4.1.1 By Drug Type

4.1.1.1 Proprietary

4.1.1.2 Non-proprietary

4.1.2 By Product

4.1.2.1 Basic building blocks

4.1.2.2 Advanced intermediates

4.1.2.3 Active ingredients

4.1.3 By Application

4.1.3.1 Cardiovascular

4.1.3.2 Neurological

4.1.3.3 Oncological

4.1.3.4 Respiratory

4.1.3.5 Gastrointestinal

4.1.3.6 Musculoskeletal

4.1.3.7 Others

4.2 Value Chain Analysis

4.3 Impact of Covid-19 on Global Pharmaceutical Fine Chemicals Market

4.4 Market Dynamics

4.4.1 Drivers

4.4.1.1 Growing geriatric population

4.4.1.2 Rapid growth of pharmaceutical sector in APAC

4.4.1.3 Impact analysis of drivers on market forecast

4.4.2 Restraints

4.4.2.1 Impact on the environment

4.4.2.2 Impact analysis of restraints on market forecast

4.4.3 Opportunities

4.4.3.1 Growing awareness in the African region

4.5 Porter’s Five Forces Analysis

4.5.1 Bargaining Power of Buyers

4.5.2 Bargaining Power of Suppliers

4.5.3 Intensity of Competitive Rivalry

4.5.4 Threat of New Entrants

4.5.5 Threat of Substitutes

Chapter 5. Regulatory Framework

5.1 U.S.

5.2 Canada

5.3 U.K.

5.4 China

5.5 Japan

5.6 South Korea

5.7 Australia

Chapter 6. Global Market Size and Forecast

6.1 By Drug Type

6.2 By Product

6.3 By Application

6.4 By Region

Chapter 7. North America Market Size and Forecast

7.1 By Drug Type

7.2 By Product

7.3 By Application

7.4 By Country

Chapter 8. Europe Market Size and Forecast

8.1 By Drug Type

8.2 By Product

8.3 By Application

8.4 By Country

Chapter 9. APAC Market Size and Forecast

9.1 By Drug Type

9.2 By Product

9.3 By Application

9.4 By Country

Chapter 10. LATAM Market Size and Forecast

10.1 By Drug Type

10.2 By Product

10.3 By Application

10.4 By Country

Chapter 11. MEA Market Size and Forecast

11.1 By Drug Type

11.2 By Product

11.3 By Application

11.4 By Country

Chapter 12. Competitive Landscape

12.1 Market Share Analysis of Key Players

12.2 Strategic Developments of Key Players

12.2.1 Mergers and Acquisitions

12.2.2 Partnerships, Collaborations, and Joint Ventures

12.2.3 Product Launches

12.2.4 Facility Expansions

12.2.5 Other Developments

12.3 List of Players and Their Offerings

Chapter 13. Company Profiles

13.1 BASF SE

13.1.1 Business Overview

13.1.2 Product and Service Offerings

13.1.3 Key Financial Summary

13.2 Eastman Chemical Company

13.2.1 Business Overview

13.2.2 Product and Service Offerings

13.2.3 Key Financial Summary

13.3 WeylChem International GmbH

13.3.1 Business Overview

13.3.2 Product and Service Offerings

13.4 Borregaard ASA

13.4.1 Business Overview

13.4.2 Product and Service Offerings

13.4.3 Key Financial Summary

13.5 Lonza Group Ltd.

13.5.1 Business Overview

13.5.2 Product and Service Offerings

13.5.3 Key Financial Summary

13.6 Clariant AG

13.6.1 Business Overview

13.6.2 Product and Service Offerings

13.6.3 Key Financial Summary

13.7 Solvay S.A.

13.7.1 Business Overview

13.7.2 Product and Service Offerings

13.7.3 Key Financial Summary

13.8 Evonik Industries AG

13.8.1 Business Overview

13.8.2 Product and Service Offerings

13.8.3 Key Financial Summary

13.9 Albemarle Corporation

13.9.1 Business Overview

13.9.2 Product and Service Offerings

13.9.3 Key Financial Summary

13.10 DuPont de Nemours Inc.

13.10.1 Business Overview

13.10.2 Product and Service Offerings

13.10.3 Key Financial Summary

13.11 Koninklijke DSM N.V.

13.11.1 Business Overview

13.11.2 Product and Service Offerings

13.11.3 Key Financial Summary

13.12 Merck KGaA

13.12.1 Business Overview

13.12.2 Product and Service Offerings

13.12.3 Key Financial Summary

Chapter 14. Appendix

Companies Mentioned

  • BASF SE
  • Eastman Chemical Company
  • WeylChem International GmbH
  • Borregaard ASA
  • Lonza Group Ltd.
  • Clariant AG
  • Solvay S.A.
  • Evonik Industries AG
  • Albemarle Corporation
  • DuPont de Nemours Inc.
  • Koninklijke DSM N.V.
  • Merck KGaA

For more information about this report visit https://www.researchandmarkets.com/r/33nxi0

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.



Media Contact:

Research and Markets

Laura Wood, Senior Manager

[email protected]   

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904

Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com

Categories
Uncategorized
No Comment

Leave a Reply

*

*

RELATED BY